morpholinoanthracycline mx2 has been researched along with Central Nervous System Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
1 trial(s) available for morpholinoanthracycline mx2 and Central Nervous System Disease
| Article | Year |
|---|---|
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Central Nervous System Diseases; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1999 |